EA201691120A1 - Векторные композиции и способы индукции усиленного иммунного ответа с использованием векторов поксвируса - Google Patents
Векторные композиции и способы индукции усиленного иммунного ответа с использованием векторов поксвирусаInfo
- Publication number
- EA201691120A1 EA201691120A1 EA201691120A EA201691120A EA201691120A1 EA 201691120 A1 EA201691120 A1 EA 201691120A1 EA 201691120 A EA201691120 A EA 201691120A EA 201691120 A EA201691120 A EA 201691120A EA 201691120 A1 EA201691120 A1 EA 201691120A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- nucleic acids
- heterologous
- induction
- immune response
- Prior art date
Links
- 239000013598 vector Substances 0.000 title 2
- 230000028993 immune response Effects 0.000 title 1
- 230000006698 induction Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000003044 adaptive effect Effects 0.000 abstract 1
- 230000000139 costimulatory effect Effects 0.000 abstract 1
- 230000005934 immune activation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002103 transcriptional effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24061—Methods of inactivation or attenuation
- C12N2710/24062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24061—Methods of inactivation or attenuation
- C12N2710/24063—Methods of inactivation or attenuation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Представленные в данном документе рекомбинантные поксвирусы, содержащие гетерологичные или природные нуклеиновые кислоты, определяющие избыток двухцепочечной РНК (дцРНК) в начале инфекции, которые могут дополнительно включать в себя гетерологичные нуклеиновые кислоты, кодирующие одну или более костимулирующих молекул, и/или гетерологичные нуклеиновые кислоты, кодирующие один или более инфекционных ассоциированных с заболеванием антигенов или опухоль-ассоциированных антигенов, а также фармацевтические композиции, содержащие такие рекомбинантные поксвирусы и способы и их использование. Рекомбинантные поксвирусы, представленные в данном документе, усиливают врожденную и адаптивную иммунную активацию у субъектов по сравнению с идентичными рекомбинантными поксвирусами, с отсутствующими гетерологичными или природными транскрипционными единицами, определяющими избыток ранней дцРНК.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13005541 | 2013-11-28 | ||
| PCT/EP2014/075522 WO2015078856A1 (en) | 2013-11-28 | 2014-11-25 | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201691120A1 true EA201691120A1 (ru) | 2016-09-30 |
| EA039037B1 EA039037B1 (ru) | 2021-11-24 |
Family
ID=49680779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201691120A EA039037B1 (ru) | 2013-11-28 | 2014-11-25 | Рекомбинантный поксвирус для усиления врожденного иммунного ответа у позвоночного и его применение |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20160376596A1 (ru) |
| EP (2) | EP3074517B1 (ru) |
| JP (2) | JP6641276B2 (ru) |
| KR (1) | KR102504316B1 (ru) |
| CN (1) | CN105829537B (ru) |
| AU (3) | AU2014356546A1 (ru) |
| BR (1) | BR112016011866A2 (ru) |
| CA (1) | CA2929600A1 (ru) |
| CY (1) | CY1124707T1 (ru) |
| DK (1) | DK3074517T3 (ru) |
| EA (1) | EA039037B1 (ru) |
| ES (1) | ES2895977T3 (ru) |
| HU (1) | HUE056105T2 (ru) |
| IL (1) | IL245509B (ru) |
| LT (1) | LT3074517T (ru) |
| MX (1) | MX2016006758A (ru) |
| MY (1) | MY188100A (ru) |
| NZ (2) | NZ719934A (ru) |
| PT (1) | PT3074517T (ru) |
| SI (1) | SI3074517T1 (ru) |
| UA (1) | UA127337C2 (ru) |
| WO (1) | WO2015078856A1 (ru) |
| ZA (1) | ZA201603187B (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3691675A1 (en) * | 2017-08-24 | 2020-08-12 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody |
| CN112996908A (zh) * | 2018-07-13 | 2021-06-18 | 亚利桑那州立大学董事会 | 用表达tnf的粘液瘤病毒治疗癌症的方法 |
| CN113573729A (zh) | 2019-01-10 | 2021-10-29 | 詹森生物科技公司 | 前列腺新抗原及其用途 |
| KR20220112241A (ko) | 2019-09-02 | 2022-08-10 | 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 | 점액종 바이러스를 이용하여 암을 치료하기 위한 새로운 종양용해성 바이러스 플랫폼 |
| IL293051A (en) | 2019-11-18 | 2022-07-01 | Janssen Biotech Inc | calr and jak2 mutant-based vaccines and their uses |
| US20240245765A1 (en) * | 2021-05-13 | 2024-07-25 | Thomas Jefferson University | Use of Ectromelia Virus for Cancer Immunotherapy and Vaccines |
| CN115043948B (zh) * | 2022-06-24 | 2024-05-28 | 青岛硕景生物科技有限公司 | 一种猴痘病毒特异性融合蛋白抗原及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5519239A (en) * | 1978-07-28 | 1980-02-09 | Green Cross Corp:The | Interferon-producing attractant |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| DK0772619T4 (da) | 1994-07-15 | 2011-02-21 | Univ Iowa Res Found | Immunmodulatoriske oligonukleotider |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| CA2678259C (en) * | 1998-12-09 | 2016-10-18 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| AU4077100A (en) * | 1999-04-08 | 2000-11-14 | Chiron Corporation | Enhancement of the immune response for vaccine and gene therapy applications |
| CN1375004A (zh) * | 1999-04-21 | 2002-10-16 | 惠氏公司 | 抑制多核苷酸序列的功能的方法和组合物 |
| WO2002042480A2 (en) | 2000-11-23 | 2002-05-30 | Bavarian Nordic A/S | Modified vaccinia ankara virus variant |
| WO2003048184A2 (en) | 2001-12-04 | 2003-06-12 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
| EP1523333A4 (en) * | 2002-07-24 | 2007-01-24 | Univ Arizona | USE OF VACCINIA VIRUS WITH DELETION OF E3L GENE AS VACCINE VECTOR |
| US20050281782A1 (en) * | 2004-06-21 | 2005-12-22 | Howard Kaufman | Novel recombinant poxvirus composition and uses thereof |
| US7998733B2 (en) * | 2004-10-05 | 2011-08-16 | Merial Limited | Chimeric vectors |
| AU2005319306B9 (en) * | 2004-12-22 | 2012-04-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| EP2042604A1 (en) * | 2007-09-26 | 2009-04-01 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | VV promoter driven overexpression of recombinant antigens |
| AU2011209175B2 (en) | 2010-01-28 | 2016-02-04 | Bavarian Nordic A/S | Vaccinia virus mutants containing the major genomic deletions of MVA |
-
2014
- 2014-11-25 AU AU2014356546A patent/AU2014356546A1/en not_active Abandoned
- 2014-11-25 MX MX2016006758A patent/MX2016006758A/es active IP Right Grant
- 2014-11-25 SI SI201431894T patent/SI3074517T1/sl unknown
- 2014-11-25 UA UAA201606912A patent/UA127337C2/uk unknown
- 2014-11-25 PT PT148062151T patent/PT3074517T/pt unknown
- 2014-11-25 EP EP14806215.1A patent/EP3074517B1/en active Active
- 2014-11-25 JP JP2016534624A patent/JP6641276B2/ja active Active
- 2014-11-25 EA EA201691120A patent/EA039037B1/ru unknown
- 2014-11-25 WO PCT/EP2014/075522 patent/WO2015078856A1/en active Application Filing
- 2014-11-25 MY MYPI2016701914A patent/MY188100A/en unknown
- 2014-11-25 DK DK14806215.1T patent/DK3074517T3/da active
- 2014-11-25 US US15/039,777 patent/US20160376596A1/en not_active Abandoned
- 2014-11-25 EP EP21190638.3A patent/EP3971298A3/en active Pending
- 2014-11-25 NZ NZ719934A patent/NZ719934A/en unknown
- 2014-11-25 LT LTEPPCT/EP2014/075522T patent/LT3074517T/lt unknown
- 2014-11-25 CA CA2929600A patent/CA2929600A1/en active Pending
- 2014-11-25 ES ES14806215T patent/ES2895977T3/es active Active
- 2014-11-25 KR KR1020167013453A patent/KR102504316B1/ko active IP Right Grant
- 2014-11-25 HU HUE14806215A patent/HUE056105T2/hu unknown
- 2014-11-25 BR BR112016011866A patent/BR112016011866A2/pt not_active Application Discontinuation
- 2014-11-25 CN CN201480062145.2A patent/CN105829537B/zh active Active
- 2014-11-25 NZ NZ759538A patent/NZ759538A/en unknown
-
2016
- 2016-05-05 IL IL245509A patent/IL245509B/en active IP Right Grant
- 2016-05-11 ZA ZA2016/03187A patent/ZA201603187B/en unknown
-
2019
- 2019-12-26 JP JP2019235645A patent/JP7050044B2/ja active Active
-
2020
- 2020-04-11 US US16/846,325 patent/US20200325477A1/en active Pending
-
2021
- 2021-02-15 AU AU2021200985A patent/AU2021200985B2/en active Active
- 2021-11-08 CY CY20211100963T patent/CY1124707T1/el unknown
-
2024
- 2024-04-30 AU AU2024202790A patent/AU2024202790A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201691120A1 (ru) | Векторные композиции и способы индукции усиленного иммунного ответа с использованием векторов поксвируса | |
| CY1123563T1 (el) | Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων | |
| EA201891415A1 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
| EA201391109A1 (ru) | Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования | |
| EA201890527A1 (ru) | Терапевтические вакцины против hpv18 | |
| BR112018011881A2 (pt) | proteínas capsidiais modificadas para liberação aumentada de vetores de parvovírus | |
| CY1120740T1 (el) | Βελτιωμενα ευλογοϊικα εμβολια | |
| PE20181529A1 (es) | Vacunas de acido nucleico para el virus varicela-zoster (vzv) | |
| EA201790413A1 (ru) | Антитела против tigit | |
| EA201690504A1 (ru) | Антигенсвязывающие белки к gitr | |
| EA201791562A1 (ru) | Антигены цитомегаловируса и их применения | |
| WO2015109124A3 (en) | Immunomodulatory agents | |
| EA201890355A1 (ru) | Новые способы индукции иммунного ответа | |
| EA201591287A1 (ru) | Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения | |
| EA201992282A1 (ru) | Усовершенствованные вакцины против вируса папилломы человека и способы их применения | |
| WO2015052543A3 (en) | Malaria vaccination | |
| PH12021550521A1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
| EA201691981A1 (ru) | Улучшенные транспортные молекулы модулярного антигена и их применение | |
| MA40624A (fr) | Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant | |
| EA201990711A1 (ru) | Новый ehv сайт инсерции orf70 | |
| PH12017501100B1 (en) | Recombinant swinepox virus and vaccines | |
| EA201990719A1 (ru) | Новые промоторы | |
| EA202090628A1 (ru) | Система экспрессии paramyxoviridae | |
| EA201990955A1 (ru) | Разработка капсидов aav | |
| MX361804B (es) | Vacunas genéticas contra el virus hendra y el virus nipah. |